[HTML][HTML] Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir …
Background Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
[HTML][HTML] Real-Life Comparison of Mortality in Non-Hospitalised Patients with SARS-CoV-2 Infection at Risk for Clinical Progression Treated with Molnupiravir or …
C Torti, PP Olimpieri, P Bonfanti, C Tascini, S Celant… - 2023 - europepmc.org
Background: Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are scarce and inconclusive. In particular, no adequately …
or with nirmatrelvir plus ritonavir are scarce and inconclusive. In particular, no adequately …
Real-Life Comparison of Mortality in Non-Hospitalised Patients with SARS-CoV-2 Infection at Risk for Clinical Progression Treated with Molnupiravir or Nirmatrevir …
C Torti, PP Olimpieri, P Bonfanti, C Tascini, S Celant… - papers.ssrn.com
Background: Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are scarce and inconclusive. In particular, no adequately …
or with nirmatrelvir plus ritonavir are scarce and inconclusive. In particular, no adequately …
[HTML][HTML] Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir …
C Torti, PP Olimpieri, P Bonfanti, C Tascini… - The Lancet Regional …, 2023 - ncbi.nlm.nih.gov
Background Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the …
C Torti, P Olimpieri, P Bonfanti, C Tascini… - THE LANCET …, 2023 - boa.unimib.it
Background: Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the …
C Torti, PP Olimpieri, P Bonfanti… - The Lancet …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
[PDF][PDF] Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir …
C Torti, PP Olimpieri, P Bonfanti, C Tascini, S Celant… - Health, 2023 - scienceopen.com
Background Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the …
C Torti, PP Olimpieri, P Bonfanti, C Tascini… - THE LANCET …, 2023 - iris.uniroma1.it
Background: Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
Real-life comparison of mortality in non-hospitalised patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrevir plus …
C Torti, PP Olimpieri, P Bonfanti, C Tascini… - THE LANCET …, 2023 - air.uniud.it
Background: Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
[HTML][HTML] Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir …
C Torti, PP Olimpieri, P Bonfanti, C Tascini… - The Lancet Regional …, 2023 - Elsevier
Background Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …